PMC:7544934 / 1323-1579 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T1","span":{"begin":187,"end":190},"obj":"https://glytoucan.org/Structures/Glycans/G00057MO"},{"id":"T2","span":{"begin":187,"end":190},"obj":"https://glytoucan.org/Structures/Glycans/G31736BK"}],"text":"oid antagonist drug, naltrexone suppresses high fat/LPS induced pro-inflammatory cytokine release both from macrophage cells and Adipose Tissue Macrophage. Moreover, Low Dose Naltrexone (LDN) also showed its activity as an ERK1/2 inhibitor. Notably, virtua"}

{"project":"LitCovid-PubTator","denotations":[{"id":"37","span":{"begin":223,"end":229},"obj":"Gene"},{"id":"45","span":{"begin":21,"end":31},"obj":"Chemical"},{"id":"46","span":{"begin":175,"end":185},"obj":"Chemical"}],"attributes":[{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"Gene:5595"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"MESH:D009271"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"MESH:D009271"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"oid antagonist drug, naltrexone suppresses high fat/LPS induced pro-inflammatory cytokine release both from macrophage cells and Adipose Tissue Macrophage. Moreover, Low Dose Naltrexone (LDN) also showed its activity as an ERK1/2 inhibitor. Notably, virtua"}

{"project":"LitCovid-sentences","denotations":[{"id":"T15","span":{"begin":156,"end":240},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"oid antagonist drug, naltrexone suppresses high fat/LPS induced pro-inflammatory cytokine release both from macrophage cells and Adipose Tissue Macrophage. Moreover, Low Dose Naltrexone (LDN) also showed its activity as an ERK1/2 inhibitor. Notably, virtua"}